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Novel n-3 Immunoresolvents: Structures
and Actions
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Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine,
Harvard Institutes of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts. 02115.
Resolution of inflammation is now held to be an active process where autacoids promote homeostasis. Using
functional-metabololipidomics and in vivo systems, herein we report that endogenous n-3
docosapentaenoic (DPA) acid is converted during inflammation-resolution in mice and by human
leukocytes to novel n-3 products congenerous to D-series resolvins (Rv), protectins (PD) and maresins
(MaR), termed specialized pro-resolving mediators (SPM). The new n-3 DPA structures include
7,8,17-trihydroxy-9,11,13,15E,19Z-docosapentaenoic acid (RvD1n-3 DPA),
7,14-dihydroxy-8,10,12,16Z,19Z-docosapentaenoic acid (MaR1n-3 DPA) and related bioactive products.
Each n-3 DPA-SPM displayed protective actions from second organ injury and reduced systemic
inflammation in ischemia-reperfusion. The n-3 DPA-SPM, including RvD1n-3 DPA and MaR1n-3 DPA, each
exerted potent leukocyte directed actions in vivo. With human leukocytes each n-3 DPA-SPM reduced
neutrophil chemotaxis, adhesion and enhanced macrophage phagocytosis. Together, these findings
demonstrate that n-3 DPA is converted to novel immunoresolvents with actions comparable to resolvins
and are likely produced in humans when n-3 DPA is elevated.
T
he resolution of acute inflammation is an active process temporally orchestrated by local-acting mediators
that limit further neutrophil recruitment to sites of inflammation1–4. During the onset of inflammation,
chemical mediators, including the arachidonic acid-derived eicosanoids (e.g. leukotriene (LT) B4 and
prostaglandin (PG) E2), mount initiation and propagation of inflammation5,6, actions that are actively
counter-regulated and orchestrated by pro-resolution agonists1,2,4. These pro-resolving autacoids also stimulate
the clearance of debris, apoptotic cells and bacteria, promoting homeostasis1,2,7.
One of the key steps during resolution of inflammation is an increase in local vascular permeability leading to
edema6,8 and the transport of n-3 essential fatty acids (EFA) from blood to the site of inflammation9. n-3 EFA are
linked with protective actions in a number of inflammatory conditions including rheumatoid arthritis10, neuro-
logical disorders11 and cardiovascular disease12. At the site of inflammation, n-3 EFA are converted to novel
potent mediators by exudate leukocytes that promote inflammation-resolution1,2,13.
The E-series resolvins, e.g. resolvin (Rv) E1, are produced from 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid
(EPA)14. The D-series resolvins, which include Resolvin D1 (7S, 8R, 17S-trihydroxy-4Z, 9E, 11E, 13Z, 15E, 19Z-
docosahexaenoic acid; RvD1) and Resolvin D2 (7S, 16R, 17S-trihydroxy-4Z, 8E, 10Z, 12E, 14E, 19Z-docosahex-
aenoic acid; RvD2), the protectins15 and maresins16 are biosynthesized from 4Z,7Z,10Z,13Z,16Z,19Z-docosahex-
aenoic acid (DHA). These potent autacoids were initially identified using temporal lipidomics with self-resolving
exudates14,15 and are now appreciated for their ability to stereo-selectively promote inflammation-resolution by
tempering leukocyte responses16,17,13. The resolvins, protectins and maresins are coined specialized pro-resolving
mediators (SPM) that by definition limit further neutrophil recruitment to the site of inflammation and promote
macrophage clearance of debris, apoptotic cells and bacteria1,2,7. In addition, the SPM exert potent actions in
promoting wound repair and tissue regeneration as well as dampening inflammatory pain16,18. Targeted lipid
mediator metabololipidomics of tissues obtained from a number of species ranging from primordial organisms
such as planaria16 to humans19,20 indicates that SPM production, including RvD1, RvE119,20 and maresin 12,14, is
evolutionarily conserved.
In mammals, alpha-linolenic acid (9Z, 12Z, 15Z-octadecatrienoic acid; ALA) is converted via elongation and
desaturation to EPA and subsequently to DHA. An intermediate in the conversion of EPA to DHA is n-3
docosapentaenoic acid (7Z,10Z,13Z,16Z,19Z-docosapentaenoic acid; n-3 DPA)10,12,21. n-3 DPA carries 22 car-
bons and contains five double bonds, with the first double bond being found on carbon 7. The structural
differences of n-3 DPA from EPA, DHA and n-6 docosapentaenoic acid (4Z, 7Z, 10Z, 13Z, 16Z,-docosapentae-
noic acid; n-6 DPA), a biochemically distinct form of DPA where the first double bond is found on carbon 4, are
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thought to confer unique biophysical properties that are of functional
relevance, for example in neuronal systems22. In humans, genome-
wide association studies demonstrate that elevation in circulating
levels of n-3 DPA and a concomitant decrease in DHA levels are
associated with single nucleotide polymorphisms in the gene encod-
ing for the fatty acid elongase 2 (ELOVL2)21. n-3 DPA is present in a
number of mammalian tissues including plasma, brain, retina and
heart at levels comparable to those of EPA and DHA23. Since cir-
culating levels of n-3 DPA in human cohorts of European, African,
Hispanic and Chinese ancestry with mutations in the ELOVL2 gene
are elevated21, we addressed hereinwhether n-3DPA is a precursor to
novel bioactive molecules. We report that endogenous n-3 DPA is
converted to novel bioactive products, determined their structures
and established their anti-inflammatory and pro-resolving actions.
Results
n-3 docosapentaenoic acid products exert potent anti-inflammatory
and tissue-protective actions in vivo. Since even minor changes in
the structural properties of EFA are of functional significance22, we
first investigated whether n-3 DPA, products that contain one fewer
double bond than those derived from DHA (Fig. 1a), produced by
exudate leukocytes exerted protective actions during acute inflam-
mation. For this purpose, we employed a model of surgery-induced
second organ injury, the murine hind limb ischemia reperfusion
model (Fig. 1b)9. Administration of an isolated mixture obtained
via solid-phase extraction (see Methods) of the n-3 DPA products
10 min prior to onset of reperfusion led to protection from second-
ary organ injury as evidenced by reduction in lung tissue damage
(Fig. 1c) and decrease in the number of infiltrated leukocytes into the
lungs (,45%, p , 0.05). These actions were comparable to pro-
tection afforded by the DHA-derived pro-resolving mediator RvD1
(Fig. 1c, d).
Assessment of whole blood neutrophil-platelet aggregates in these
mice, a marker of systemic inflammation24, following administration
of n-3 DPA products or RvD1 gave a significant reduction (55–65%)
in the levels of platelet-leukocyte aggregates found 2 h post reperfu-
sion (Fig. 1e).
Using targeted lipid mediator metabololipidomics, we next
assessed whether these n-3 DPA products also regulated pro-
inflammatory eicosanoid biosynthesis following ischemia reperfu-
sion. Administration of these products led to a significant reduction
in plasma prostanoid levels including PGE2 (,75%) and thrombox-
ane B2 (TxB2) (,80%; Fig. 1F). Here we also found a significant
reduction in plasma LTB4 (,60%) levels along with a decrease in
levels of its double di-oxygenation isomer 5S,12S-diHETE (,75%;
Fig. 1g). Of note the n-3 DPA products displayed equal or higher
potency at regulating plasma eicosanoid levels when compared to
RvD1 (Fig. 1f, g). These results demonstrate that n-3 DPA products
possess potent anti-inflammatory and tissue-protective actions,
regulating leukocyte recruitment, pro-inflammatory mediator bio-
synthesis and systemic inflammation.
Targeted metabololipidomics of plasma following ischemia
reperfusion injury. Having found that n-3 DPA products display
potent actions during ischemia reperfusion, we next investigated the
role of endogenous n-3 DPA derived in the control of acute
inflammation. First we assessed the plasma levels of unesterified
arachidonic acid (AA), eicosapentaenoic acid (EPA), n-3 docosa-
pentaenoic acid (DPA) and docosahexaenoic acid (DHA) in mice
that were not subjected to an inflammatory stimulus. Plasma AA
levels were 573.0 ng/ml, EPA levels were 116.2 ng/ml, n-3 DPA
levels were 66.3 ng/ml and DHA levels were 146.1 ng/ml.
Following ischemia reperfusion injury, circulating values for all 4
PUFA were elevated, with levels for n-3 DPA increasing ,12 times
to those found in uninjured mice (Fig. 2a).
We next sought evidence for the conversion of n-3 DPA to bioac-
tive mediators during acute inflammation. Using lipid mediator
metabololipidomics and monitoring the precursor ion m/z 345 in
Q1 and the product ion m/z 327 in Q3, we found three major pro-
ducts eluting in LC-peaks (Fig. 2b). Analysis of the tandem mass
spectra (MS-MS) for the products under each peak demonstrated
that peak I, at retention time (RT) 5 17.1 min, corresponded to 17-
HDPA (Supplementary Fig. 1a), the peak at RT 5 17.3 min (peak II)
to 14-HDPA (Supplementary Fig. 1b) and peak III at RT 5 17.6 min
corresponded to 7-HDPA (Supplementary Fig. 1c). Quantification of
these novel products by multiple reaction monitoring (MRM) in the
plasma of uninjured mice and mice subjected to ischemia reperfu-
sion demonstrated that all three products were elevated following
ischemia reperfusion injury (Fig. 1c). These results demonstrate that
during acute inflammation, systemic n-3 DPA levels are elevated,
and this n-3 EFA is converted to novel oxygenated products.
Chiral metabololipidomics of endogenous n-3 DPA products. In
order to elucidate the biosynthetic origins of these novel n-3 DPA-
derived products we designed chiral metabololipidomic profiling of
the n-3 DPA products generated in vivo. Reverse-phase chiral LC-
MS-MS metabololipidomics of plasma samples obtained from mice
subjected to ischemia reperfusion injury achieved baseline separa-
tion of 7R/S-HDPA, 14R/S-HDPA and 17R/S-HDPA (Supplemen-
tary Fig. 2). Quantification of the two isomers for each of the
products identified demonstrated that the R to S ratio for all of the
monohydroxy products identified was ,20%5,80%. These results
indicated that the conversion of n-3 DPA to these novel products is
enzymatically regulated, since mammalian lipoxygenases are known
to insert molecular oxygen in predominantly the S configuration5.
Targeted metabololipidomics during onset and resolution of
acute inflammation uncovers novel n-3 docosapentaenoic acid
products. Having found that n-3 DPA is converted in vivo to yield
monohydroxy acids that predominantly possess the S chirality, we
next investigated whether these n-3 DPA monohydroxy products
were precursors and/or pathway markers for the biosynthesis of
bioactive mediators. To this end, we employed targeted LM
metabololipidomics with plasma from mice subjected to ischemia
reperfusion injury. Multiple reaction monitoring of m/z 377 in Q1
and m/z 143 in Q3 yielded two peaks, the first at RT 5 11.6 min and
the second at RT 5 12.1 min (Fig. 3a). Inspection of the MS-MS
spectrum for the product eluting in peak at RT 5 11.6 min
demonstrated that this material corresponded to RvD2n-3 DPA with
the following characteristic ions assigned: m/z 307, m/z 279, m/z 249,
m/z 233, and m/z 143 (c.f. Supplementary Fig. 3a, b); while
assessment of the MS-MS spectrum for the products at RT 5
12.1 min demonstrated that this material corresponded to RvD1n-3
DPA (Fig. 3b).Multiple reactionmonitoring ofm/z 361 inQ1 andm/z
263 inQ3 yielded three peaks, one at RT 5 13.6 min, the second peak
with RT 5 13.7 min and the third peak RT 5 14.4 min (Fig. 3a).
Assessment of MS-MS spectra for the product with RT 5 13.6 min
gave characteristic fragmentation corresponding to RvD5n-3 DPA
(Fig. 3c). MS-MS fragmentation for the material at RT 5 13.7 min
demonstrated characteristic fragmentation corresponding to PD1n-3
DPA (Fig. 3d). The peak eluting at RT 5 14.4 min was identified as
PD2n-3 DPA with the following characteristic ions assigned: m/z 233,
m/z 247, m/z 189 (c.f. Supplementary Fig. 4c, d). These findings
demonstrate that n-3 DPA is converted to novel products that are
cognate to pro-resolving mediators from DHA; therefore, we
employed the nomenclature from the DHA bioactive metabolome
to describe each of these new structures.
Since vascular leakage during inflammation supplies the site of
inflammation with PUFA9, we next investigated tissue levels of n-3
DPA products during the onset and resolution of inflammation. For
this purpose, we applied a self-limitedmodel of inflammation where,
following the administration of a pro-inflammatory stimulus into the
www.nature.com/scientificreports
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mouse peritoneum, there is a rapid recruitment of neutrophils into
the site that peaks at around 6 h (Tmax; Fig. 4a). This is followed by a
decline in neutrophil numbers over the next 18 h. The time differ-
ence between Tmax and the point where neutrophil numbers reach
50% of maximum (T50) is defined as the resolution interval (Ri)25.
Using LM metabololipidomics, we profiled the levels of LTB4 and
PGE2 that were rapidly produced during the initiation phase of the
inflammatory response concomitant with neutrophil infiltration into
the tissue (Fig. 4b). Maximal LTB4 levels coincided with peak neu-
trophil infiltration, whereby LTB4 levels rapidly subsided over the
next 8 h. PGE2 levels were also elevated early in the initiation phase
of the response, with levels for this mediator persisting into the
Figure 1 | n-3 DPA-derived products display potent anti-inflammatory and tissue protective actions in vivo that are comparable to RvD1.
(a) Structures of DHA and n-3 DPA. (b) Ischemia was induced by applying tourniquets to the hind limb of 6-8-week-old male FvB mice. After 1 h,
tourniquets were removed and reperfusion ensued for 3 h. 10 min prior to reperfusion, vehicle (saline containing 0.1% EtOH), RvD1 (500 ng) or a
mixture of n-3 DPA-derived products (see Methods for details) were administered intravenously. At the end of reperfusion, lungs were collected;
(c) tissue histology by H&E staining (x200) and (d) MPO levels were assessed. (e) Blood was collected, incubated with rat anti-mouse Ly6G and rat anti-
mouse CD41 antibodies and neutrophil leukocyte aggregates were assessed by flow cytometry. (f) Plasma prostanoid and (g) leukotriene levels were
assessed by lipid mediator metabololipidomics. Results c are representative n 5 4. Results d–e are mean 6 SEM. n 5 4. * P , 0.05, ** P , 0.01 vs.
vehicle mice.
www.nature.com/scientificreports
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Figure 2 | n-3DPA levels increase in acute inflammation and is converted to novel products in vivo. Mice were subjected to ischemia reperfusion injury
(see Methods for details) at 2 h of reperfusion, blood was collected via cardiac puncture and plasma was obtained by centrifugation, products were
extracted and monohydroxy n-3 DPA levels were assessed by lipid mediator metabololipidomics. (a) Plasma polyunsaturated fatty acid levels;
(b) Representative chromatographs obtained byMultiple ReactionMonitoring (MRM) of the parent ion (Q1)m/z 345 and a diagnostic daughter ion (Q3)
m/z 327. (c) Monohydroxy-containing levels in plasma of shammice andmice subjected to I/R. Results for a and c are mean 6 SEM. n 5 4. Results for b
are representative of n 5 4. *P , 0.05; **P , 0.01; ***P , 0.01 vs. sham mice.
www.nature.com/scientificreports
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resolution phase. In this experimental setting, which characterizes the
initiation and resolution phases of the inflammatory response25, we
determined the profile of novel n-3 DPA products in order to tem-
porally stage each of these new products within the self-limited
inflammatory response. Here we found that endogenous production
of RvD1n-3 DPA and PD2n-3 DPA displayed a bi-phasic profile, rea-
ching a maximum during peak neutrophil infiltration and late into
resolution (Figure 4c, d). PD1n-3 DPA, MaR2n-3 DPA and MaR3n-3 DPA
levels were each found to reach a maximum at the 4h interval and
gradually decreased over the next 20 h (Figure 4d, e). The peak in
exudate RvD2n-3 DPA levels coincided with the onset of resolution (the
point where PMN levels reach,50 of Tmax). RvD5n-3 DPA levels were
found to gradually increase over the course of inflammation-
resolution, with a maximum being reached late in the resolution phase.
The n-3 DPA product corresponding to MaR1n-3 DPA gave levels that
were elevated in the peritoneum of naive mice, where upon challenge
with zymosan these levels drastically decreased. Also, MaR1n-3 DPA
accumulated late during resolution (Figure 4e). These results establish
the endogenous production of novel n-3 DPA resolvins, protectins and
maresins during acute inflammation and stage their formation prim-
arily within the self-limited inflammatory response.
Specialized pro-resolving mediators from n-3 DPA exert potent
anti-inflammatory actions in vivo. We next tested whether these
novel structures carried bioactivity. Intravenous administration of
100 ng of RvD1n-3 DPA and RvD2n-3 DPA significantly reduced
neutrophil recruitment into the peritoneum (A; ,45%; Fig. 5a). In
these experiments, we also found that the novel tri-hydroxy-
containing n-3 DPA products significantly reduced exudate levels
of the pro-inflammatory cytokines Interleukin (IL) 6 (,55%;
Fig. 5b) and monocyte chemoattractant protein (MCP)-1 (,55%;
Fig. 5c). Administration of the di-hydroxy-containing n-3 DPA
products from both 17-hydroperoxy-DPA (HpDHA; RvD5n-3 DPA
and PD1n-3 DPA; B; ,47%) and 14-HpDPA (MaR1n-3 DPA and
MaR2n-3 DPA; C; ,50%) also significantly reduced PMN
recruitment and pro-inflammatory cytokine levels in these exudates
(Fig. 5a–c).
Human leukocytes produce n-3 DPA immunoresolvents. Having
found that these products are produced in murine systems, we next
sought evidence for their production by human leukocytes.
Assessment of methyl formate fractions obtained from activated
human peripheral blood neutrophils incubated with n-3 DPA by
lipid mediator metabololipidomics profiling gave products that
displayed chromatographic and MS-MS spectra consistent with
resolvins, protectins and maresins that carry the n-3 DPA
backbone (Fig. 5a). Assessment of the UV absorbance spectra and
MS-MS fragments for each of the products gave fragment ions that
Figure 3 | Identification of novel endogenous n-3 DPA pro-resolving mediators. Mice were subjected to ischemia reperfusion injury (see Methods and
Fig. 2 for details). Two h into reperfusion, blood was collected and lipid mediators identified by lipid mediator metabololipidomics. (a) Representative
chromatographs obtained byMultiple ReactionMonitoring of the parent ion (Q1) and a diagnostic daughter ion (Q3) in theMS-MS of n3-DPA resolvins,
protectins and maresins. Representative MS-MS spectra used for identification of (b) RvD1n-3 DPA, (c) RvD5n-3 DPA, and (d) PD1n-3 DPA. Results are
representative of n 5 4.
www.nature.com/scientificreports
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were consistent with RvD2n-3 DPA with m/z 377 [M-H], m/z 359
[M-H-H2O] and m/z 333 [M-H-CO2] (Fig. 5a and Supplementary
Fig. 3a, b). Additional diagnostic ions were identified at m/z 247, m/z
143 and m/z 279 consistent with the presence of hydroxy groups at
carbon positions 7, 16 and 17. In the tri-hydroxy chromatographic
regions, we also identified RvD1n-3 DPA as demonstrated by its
characteristic fragmentation pattern and UV absorbance spectra,
consistent with hydroxyl groups at the carbon 7, 8 and 17
positions (Fig. 3a, b and Supplementary Fig 3c, d). Assessment of
the UV absorbance and MS-MS spectra in the di-hydroxy region
Figure 4 | Self-limited inflammation: Endogenous formation of novel immunoresolvents from n-3 DPA. Mice were treated with 0.1 mg zymosan i.p.;
after the indicated time intervals peritoneal exudates were collected. (a) Exudate leukocyte counts obtained by light microscopy and flow cytometry.
Exudate levels for (b) prostaglandin (PG) E2 and leukotriene (LT) B4; (c) resolvins, (d) protectins and (e) maresins were measured by lipid mediator
metabololipidomics. Results are mean 6 SEM. n 5 4 mice per time point.
www.nature.com/scientificreports
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revealed the presence of RvD5n-3 DPA (Fig. 3a, c and Supplementary
Fig 3e, f), PD1n-3 DPA (Fig. 3a and Supplementary Fig. 5a, b) and
MaR3n-3 DPA (Fig. 3a and Supplementary Fig. 5e, f). Using LM
metabololipidomics we also found that human monocyte-derived
macrophages produce resolvins, protectins and maresins from
endogenous n-3 DPA (n 5 3). These findings demonstrate that
human leukocytes can convert both exogenous as well as endo-
genous n-3 DPA to novel n-3 DPA immunoresolvents.
n-3 DPA products exert anti-inflammatory and pro-resolving
actions on human leukocytes. We next investigated whether these
novel n-3 DPA products retained their leukocyte directed anti-
inflammatory and pro-resolving actions when incubated with
human leukocytes. A key step in neutrophil recruitment to the site
of inflammation is firm adhesion to the vascular endothelium26.
Incubation of neutrophils with RvD1n-3 DPA and RvD2n-3 DPA, (A;
,30%), RvD5n-3 DPA and PD1n-3 DPA, (B;,25%) or PD1n-3 DPA and
PD2n-3 DPA (C; ,22%) led to a significant reduction in neutrophil
adhesion to TNF-a activated endothelial cells to a similar extent as
RvD2 (,30%; Fig. 7a), a potent pro-resolving mediator27.
Neutrophil-endothelial cell adhesion is mediated by adhesion
molecules expressed on both the endothelial and neutrophil surface
that are up-regulated during inflammation26. One of these adhesion
molecules is Intercellular Adhesion Molecule 1 (ICAM-1/CD54)
expressed on endothelial cells28. Incubation of each of the n-3 DPA
products with endothelial cells prior to incubation with TNF-a also
led to a significant reduction in endothelial cell ICAM-1 expression
(,25–40%; Fig. 5b).
We next questioned whether the n-3 DPA pro-resolving media-
tors regulated human peripheral blood leukocyte recruitment to a
chemotactic stimulus. Incubation of human leukocytes with RvD2
led to a significant reduction in neutrophil (,42%) recruitment
towards an IL-8 gradient. When human neutrophils were incubated
with RvD1n-3 DPA and RvD2n-3 DPA (1 nM), we also found a signifi-
cant reduction in neutrophil chemotaxis (,45%) towards an IL-8
gradient (Fig. 7b). Incubation of human neutrophils with 1 nMof the
di-hydroxy containing products (i.e. RvD5n-3 DPA and PD1n-3 DPA, C;
or MaR1n-3 DPA and MaR2n-3 DPA, D) also led to a significant reduc-
tion in neutrophil chemotaxis (,40–75%) towards IL8 (Fig. 7b).
Because macrophage clearance of cellular debris and apoptotic
cells is a critical process in promoting the resolution of acute inflam-
mation1, we next incubated human monocyte-derived macrophages
with RvD2, which led to a significant increase in the uptake of opso-
nized zymosan particles (,50%; Fig. 7c). Addition of RvD5n-3 DPA
and PD1n-3 DPA, (1 nM) tomacrophages each also led to a significant
increase (,70%) in macrophage phagocytosis of fluorescently
labeled zymosan (Fig. 7c). Macrophage incubations with MaR1n-3
DPA and MaR2n-3 DPA (,55%) or RvD1n-3 DPA and RvD2n-3 DPA
(,45%) also gave significant increases in macrophage uptake of
fluorescently labeled zymosan (Fig. 7c). These results demonstrate
that the novel n-3 DPA mediators exert potent anti-inflammatory
and pro-resolving actions with human leukocytes limiting human
neutrophil recruitment andmacrophage phagocytosis, key processes
in promoting resolution and by definition those assigned to pro-
resolving mediators1,2.
Discussion
In the present report, using lipid mediator metabololipidomics, we
identified novel n-3 DPA-derived products and staged their biosyn-
thesis during self-limited inflammation in inflammatory exudates.
With murine models of acute inflammation and human leukocytes,
we determined their anti-inflammatory, pro-resolving and tissue
protective actions, defining these novel n-3 DPA products as immu-
noresolvents.
In humans, circulating n-3 DPA levels do not appear to be directly
associated with dietary intake, unlike other n-3 EFA including DHA
and EPA21,29, thus suggesting in humans a primary endogenous
metabolic origin for n-3 DPA. Along these lines, a recent genome
wide association study with more then 8500 participants from vari-
ous ethnicities demonstrated that elevated plasma n-3 DPA levels are
Figure 5 | n-3 DPA immunoresolvents display potent anti-inflammatory
actions in vivo. The indicated n-3 DPA-derived product mixtures were
administered by intravenous injection 10 min prior to the intraperitoneal
administration of zymosan (0.1 mg, 500 ml PBS) to 6–8-week-old male
FvBmice. At 4 h, peritoneal exudates were collected and the (a) number of
infiltrated neutrophils was assessed by light microscopy and flow
cytometry. Exudate levels for the pro-inflammatory mediators (b) IL6 and
(c)MCP-1 were determined by cytokine array. The ratio of RvD1n-3 DPA to
RvD2n-3 DPA was,351 (A), the ratio of MaR1n-3 DPA to MaR2n-3 DPA was
,451 (B); the ratio of RvD5n-3 DPA to PD1n-3 DPA was ,951 (C). Results
are mean 6 SEM. n 5 4. * P , 0.05, ** P , 0.01 vs. zymosan mice.
www.nature.com/scientificreports
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associated with single nucleotide polymorphisms in the genes encod-
ing for the fatty acid elongase 2 (ELOVL2) and glucokinase regula-
tory protein (GCKR)21. This increase in n-3 DPA levels is also
associated with a reduction in circulating DHA levels. Of interest,
circulating n-3 DPA has been associated with protection from
cardiovascular disease30–32. Hence, our present findings indicating
that n-3 DPA is a precursor to new potent bioactive products may
have wide implications in individuals carrying elevated circulating
levels of n-3 DPA.
Ischemia-reperfusion injury is of considerable consequence in
the pathology of many diseases including periodontal disease,
arthritis and stroke as well as being of relevance during surgical
procedures, in particular those involving extremities, causing
aberrant leukocyte activation that results in local and remote tis-
sue and organ damage33. Neutrophils in these settings play pivotal
roles in the perpetuation of reperfusion injury giving rise to
second organ injury33. However, phagocytes, including neutrophils
when appropriately activated, are also instrumental in orchestrat-
ing resolution processes via their temporal production of
pro-resolving mediators in resolving exudates14,15,34,35. Hence our
findings indicating that n-3 DPA products obtained from phago-
cytes collected from self-resolving exudates display potent protect-
ive actions from second organ injury during ischemia reperfusion
have implications in a wide range of human pathologies. Indeed
these products markedly reduced both local tissue damage and
neutrophil infiltration into the lungs (Fig. 1), a hallmark of second
organ injury, to a similar extent as the DHA-derived resolvin D1,
a known potent pro-resolving mediator9.
The formation of platelet-leukocyte aggregates in the vasculature
is also a component of many inflammatory disorders including
stroke, sepsis and hypertension. Formation of these microcellular
aggregates enhances the production of a number of pro-inflammat-
ory cytokines including IL-8 and MCP-1 as well as increases the
levels of platelet aggregating factor, a potent pro-inflammatory lipid
mediator (for a review, see ref. 24). In this context, elevated levels of
circulating platelet-leukocyte aggregates are proposed as an early
marker for acutemyocardial infarction and are increasingly regarded
as a cardiovascular risk factor36. In the present studies, adminis-
tration of phagocyte-derived n-3 DPA products led to a reduction
in circulating platelet-neutrophil aggregates following ischemia
Figure 6 | Human neutrophils produce novel n-3 DPA-derived immunoresolvents. Human neutrophils were prepared from peripheral blood (see
Methods for details), suspended in DPBS (80 3 106/ml) and incubated with serum treated zymosan (0.1 mg) and n-3 DPA (1 mM, 30 min, 37uC, pH
7.45); incubations were stoppedwith ice-coldmethanol and products assessed by lipidmediatormetabololipidomics. (a) Representative chromatographs
obtained byMultiple ReactionMonitoring of the parent ion (Q1) and a diagnostic daughter ion (Q3) in theMS/MS. Representative MS/MS spectra used
for identification of (b) RvD1n-3 DPA and (c) RvD5n-3 DPA. Results are representative of n 5 4.
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reperfusion injury. In addition, we also found a substantial reduction
in plasma pro-inflammatory eicosanoid levels including LTB4 and
TxB2 (Fig. 1), actions that were comparable to those afforded by
DHA-derived RvD1. Therefore, these results demonstrate that n-3
DPA products display potent systemic anti-inflammatory and tissue
protective actions.
Phagocytes carry lipoxygenase enzymes that are involved in
the biosynthesis of pro-resolving mediators14,15,35. These enzymes
convert their substrate in a stereospecific manner, inserting molecu-
lar oxygen predominantly in the S configuration5,34. In the present
study we found that the systemic levels of n-3 DPA and the new n-3
DPA products (i.e. 17-HDPA, 14-HDPA and 7-HDPA) were each
elevated during acute inflammation in vivo (Fig. 2). In addition,
chiral lipidomics of these n-3 DPA products demonstrated that the
hydroxy groups in these products were predominantly in the S con-
figuration suggesting that each was produced via lipoxygenases
(Supplementary Fig. 2). Targeted metabololipidomics demonstrated
that n-3 DPA is further oxygenated, in both murine in vivo and
isolated human leukocytes, to products that are congenerous of
the DHA-derived pro-resolving mediators (Figs. 3, 6). In addition,
endogenous levels of these novel n-3 DPA mediators were tempor-
ally regulated during self-limited inflammation suggesting that each
may possess distinct roles in the regulation of inflammation-
resolution and in organ protection (Fig. 4).
Figure 7 | Reduction in human neutrophil chemotaxis, neutrophil-endothelia cell adhesion and stimulation of macrophage phagocytosis by n-3
DPA-derived immunoresolvents. (a) Left panel: micrographs depict PKH26-labeled neutrophils adherent to WGA-AlexafluorH 488-labeled HUVEC
stimulated with TNF-a (10 ng/ml, 4 h, 37uC, 0.1% FCS) with or without n-3 DPA resolvins (1 nM, 15 min, 37uC, pH7.45; 340 magnification). Right
panel: Fluorescently labeled human neutrophils were incubated with vehicle (0.1%EtOH in PBS) or n-3DPA products. These were then added to TNF-a-
stimulatedHUVEC and incubated for 30 min (37uC), non-adherent cells were washed and extent of neutrophil adhesion assessed using a SpectraMaxM3
Plate reader. (b) Neutrophils were incubated with vehicle (0.1% EtOH in PBS) or n-3 DPA products (1 nM, 15 min, 37uC, pH7.45) prior to loading on
ChemoTx chambers and assessing chemotaxis towards IL-8 (100 ng/ml, 90 min, 37uC, pH7.45). (c) Macrophages were incubated with vehicle (0.1%
EtOH in PBS) or n-3 DPA products (1 nM, 15 min, 37uC, pH7.45) prior to addition of fluorescently labeled zymosan (1510 macrophages to zymosan).
After 60 min (37uC, pH7.45), the incubation was stopped, extracellular fluorescence quenched using trypan blue and phagocytosis assessed using a
SpectraMax M3 Plate reader. The ratio of RvD1n-3 DPA to RvD2n-3 DPA (A) was,351; the ratio of RvD5n-3 DPA to PD1n-3 DPA (B) was,951; the ratio of
PD1n-3 DPA to PD2n-3 DPA (C)was,155; the ratio ofMaR1n-3 DPA toMaR2n-3 DPA (D)was,451. Results aremean6 SEM. n5 4 independent neutrophil
and macrophage preparations (*P , 0.05; **P , 0.05 vs. vehicle incubated cells). Bar 5 50 mM.
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In light of the results from the present studies in conjunction
with earlier mechanisms proposed for the biosynthesis of the D-
series resolvins, protectins15,34 and maresins35, the pathways for the
novel n-3 DPA immunoresolvent are illustrated in Fig. 8. In this
proposed scheme, n-3 DPA is first converted via 17 lipoxygena-
tion to 17-hydroperoxy-8Z,10Z,13Z,15E,19Z-docosapentaenoic
acid (17-HpDPA). This intermediate can next undergo a second
lipoxygenation by 5-lipoxygenase-like reaction to yield the 7,8,
17-trihydroxy-9,11,13,15E,19Z-docosapentaenoic acid (RvD1n-3DPA),
7, 16, 17-trihydroxy-8,10,12,14E,19Z-docosapentaenoic acid
(RvD2n-3DPA) and/or 7,17-trihydroxy-8E,10,13,15E,19Z-docosapen-
taenoic acid (RvD5n-3DPA). In addition, 17-HpDPA can undergo
Figure 8 | Biosynthetic schemes proposed for novel n-3 docosapentaenoic acid products and their actions. At the site of injury, n-3 DPA is converted to
(a) 17-HpDPA that undergoes further conversion by lipoxygenation to the n-3 DPA resolvins. 17-HpDPA is also a substrate for enzymatic conversion to
an epoxide intermediate that is next enzymatically hydrolyzed to the n-3 DPA protectin structures. (b) n-3DPA is also converted to 14-lipoxygenation to
yield 14-HpDPA that is further converted to an epoxide intermediate and then enzymatically hydrolyzed toMaR1n-3 DPA and/orMaR2n-3 DPA. 14-HpDPA
can also undergo a second oxygenation at the omega 21 position to yield the MaR3n-3 DPA. Note that each product is depicted in the 17S and 14S
configuration based on the results obtained from chiral lipidomics that indicated S as the predominate form of each but may also carry 17R as well as 14R
chirality from lipoxygenase reactions as these lesser components (see Supplementary Fig. 2 and text for details). The complete stereochemistries of these
novel mediators remain to be established and are depicted in their likely configuration based on biogenic synthesis (see Supplementary Figures 3–5 for
retention times, UV and MS-MS for each of these mediators).
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enzymatic conversion to an epoxide intermediate that is next enzy-
matically hydrolyzed to either 10,17-dihydroxy-7Z,11,13,15,19Z-
docosapentaenoic acid (PD1n-3DPA) or 16,17-dihydroxy-7Z,10,13,
14,19Z- docosapentaenoic acid (PD2n-3DPA). In a parallel pathway,
the arachidonate 12-lipoxygenase coverts n-3 DPA to 14-hydroper-
oxy-7Z,10 Z,12E,16Z,19Z-docosapentaenoic acid (14-HpDPA) that
is further converted to an epoxide intermediate and then enzy-
matically hydrolyzed to yield 7,14-dihydroxy-8,10,12,16Z,19Z-
docosapentaenoic acid (MaR1n-3 DPA) or 13,14-dihydroxy-7Z,9,11,
16Z,19Z-docosapentaenoic acid (MaR2n-3 DPA). Alternatively, this
14-HpDPA can undergo a second oxygenation at the omega -1
position to yield 14, 21-dihydroxy-7Z,10Z,12E,16Z,19Z-docosapen-
taenoic acid (MaR3n-3 DPA). Of note, since we identified the S isomer
of both 17-HDPA and 14-HDPA, the reduction products of 17-
HpDPA and 14-HpDPA, as the major products in inflamed tissues
(Supplementary Fig. 2), it is highly likely that the stereochemistry at
these positions is retained in the biosynthesis of the novel n-3 DPA-
derived resolvins, protectins and maresins. Of note, it is conceivable
that the R-containing diastereomers of the n-3 DPA resolvins, pro-
tectins and maresins may also be of biological relevance in inflam-
mation-resolution, since they were also obtained via lipoxygenation
reaction albeit to lesser proportions than their corresponding R-con-
taining products (see Supplementary Fig. 2).
Excessive neutrophil activation and infiltration to the inflamed site
can be detrimental since it may lead to further tissue damage and
propagation of the inflammatory response4,13. When administered in
vivo, RvD1n-3 DPA, RvD2n-3 DPA, RvD5n-3 DPA, PD1n-3 DPA,MaR1n-3 DPA,
and MaR2n-3 DPA each reduced neutrophil infiltration in murine
peritonitis (Fig. 5). These mediators also demonstrated potent cyto-
kine counter-regulatory actions reducing exudate levels of IL-6 and
MCP-1 (Fig. 5) to levels comparable with the pro-resolving mediator
RvD227. The novel n-3 DPA immunoresolvents were also found to
exert potent anti-inflammatory actions with human neutrophils and
endothelial cells regulating central steps in the leukocyte recruitment
cascades, reducing neutrophil chemotaxis and adhesion to endothe-
lial cells (Fig. 7) as well as expression of the adhesionmolecule ICAM-
1 by endothelial cells (Supplementary Fig. 6). Importantly, these
mediators were found to enhance macrophage phagocytosis, a key
process in accelerating the onset or resolution (Fig. 7)1,4,37. Thus, the
actions for each of these novel n-3 DPA products are in accord with
the key characteristic that define an immunoresolvent, a property
shared with their DHA resolution metabolome SPM counterparts.
Since mammals lack enzymes that can insert double bonds in
either the n-3 or n-6 position to polyunsaturated fatty acids, the
precursor molecules for the production of n-3 and n-6 essential fatty
acids, namely alpha linolenic acid (ALA) and linoleic acid (9Z,12Z-
octadecadienoic acid), must be obtained via dietary intake12. Inmam-
malian tissues, ALA is converted by elongation and desaturation to
EPA and DHA. Linoleic acid on the other hand is converted, in a
parallel pathway in humans, to arachidonic acid and subsequently to
n-6 DPA10,12. Thus, while n-3 DPA and n-6 DPA each share the
carbon 22 and five unsaturated double bonds, their structures are
different because they are produced via separate biosynthetic path-
ways from chemically dissimilar precursors and each possesses dis-
tinct biophysical properties22. Earlier, oxygenated products obtained
from n-6 DPA were found to reduce neutrophil recruitment in a
model of dermal inflammation38, enhance macrophage phagocyt-
osis39, reduce ear swelling in a model of delayed type hypersensitiv-
ity38 and protect against intestinal damage in a mouse model of
intestinal inflammation39, albeit displaying lower potency then the
n-3 pro-resolving mediators1 as well as compared to the new n-3
DPA mediators described herein. This is in accord with the finding
that even subtle differences in the stereochemistry of lipid mediators
can result in dramatic changes in their potency34.
In summary, herein we established the structures of new n-3DPA-
derived products, their formation from endogenous sources, staged
the production of each of these novel mediators during-inflam-
mation resolution and determined their anti-inflammatory, pro-
resolving and tissue protective properties. These actions are char-
acteristic of specialized pro-resolving mediators37 and define these
novel n-3 DPA products as immunoresolvents. In view of the role of
lipidmediators in inflammation and its timely resolution1,4,37, the n-3
DPA metabolome documented herein may mediate some of the
beneficial actions associated with probiotic dietary supplementa-
tion40. Moreover, these new n-3 immunoresolvents may also serve
as a compensatory mechanism in people with elevated n-3 DPA
levels and lower circulating DHA levels21 to compensate for losses
in DHA SPM-regulated leukocyte-mediated tissue damage and
timely resolution of acute inflammation.
Methods
Materials. Zymosan A, bovine serum albumin (BSA), Roswell Park Memorial
Institute media 1640 (RPMI 1640), DPBS and Histopaque 1077-1 were purchased
from Sigma-Aldrich. Rat anti-mouse Ly6G (clone 1A8; BD Biosciences); rat anti-
mouse F4/80 (clone: BM8), CD11b (clone: Mac-1) and CD41 (clone: eBioMWReg30)
were from eBioscience. Human recombinant granulocyte-monocyte colony
stimulating factor (GM-CSF) and LC grade solvents were purchased from Fisher
Scientific; Agilent Eclipse C18 (4.6 mm 3 100 mm 3 1.8 mm; 4.6 mm 3 50 mm 3
1.8 mm) column; C18 SPE columns (Biotage); fluorescently conjugated Zymosan A
(Invitrogen); LC-MS-MS quantification and deuterated internal standards (d8-5S-
hydroxyeicosatetraenoic acid (d8-5S-HETE), d4-LTB4, d5-lipoxin A4 (d5-LXA4),
d4-PGE2, RvD1, RvD2; Cayman Chemicals).
Animals. All animals used in the present study were male FVB mice (Charles River
Laboratories) that were 6–8weeks old (weighing 20–25 g). Theyweremaintained in a
temperature-and light-controlled environment and had unlimited access to water
and food (laboratory standard rodent diet 5001 (Lab Diet)), containing 1.5%
eicosapentaenoic acid, 1.9%DHA of total fatty acids. Experiments were performed in
accordance with the Harvard Medical School Standing Committee on Animals
guidelines for animal care (Protocol 02570).
n-3 DPA-derived mediator preparations. Exudates were obtained from mice 12 h
after zymosan administration and incubated with n-3 DPA in DPBS (1 mM, 45 min,
37uC, pH 7.45); the incubations were stopped using 2 volumes of ice-cold methanol
and products extracted as outlined in the sample extraction and lipid mediator
metabololipidomics section below.
14S-HpDPA was prepared from n-3 DPA (,15 mM) incubated with 5.4 U/ml
isolated 12-lipoxygenase (LOX) (porcine) (0.05 M phosphate buffer, 0.02% Tween
20, pH 7.4). 14S-HpDHA was isolated via RP-HPLC (1100 Series; Agilent
Technologies) using a C18 column and a mobile phase consisting of methanol/water
(60520, vol/vol) at 0.5 ml/min that was ramped up to 9852 vol/vol over for 20 min.
Reduction with NaBH4 yielded 14S-HDPA used for mass spectrometry standard. In
determined incubations 14S-HpDPAwas incubated with humanmacrophages (403
106/ml) or neutrophils (80 3 106/ml) in PBS (containing calcium and magnesium)
and serum treated zymosan (StZ, 0.1 mg/ml); the incubations were stopped after
45 min and products extracted.
17S-HpDPA was prepared from n-3 DPA (,15 mM) incubated with 100 U/ml
isolated soybean-LOX (Borate buffer, 4uC, pH 9.2). 17S-HpDHAwas isolated via RP-
HPLC. Reduction with NaBH4 yielded 17S-HDPA used for mass spectrometry
standard. Biogenic synthesis of the di- and tri- dioxygenation products was per-
formed with 5-LOX enzyme (200 U/ml) incubated with 17S-HpDPA. In determined
incubations, 17Hp-DPA was added to human macrophages (40 3 106/ml) or neu-
trophils (80 3 106/ml) in PBS (containing calcium and magnesium) and cells were
then incubated with StZ (0.1 mg/ml), incubations were stopped after 45 min and
products extracted. These were scaled up for direct comparison of biological and
physical properties with other novel compounds isolated from peripheral blood
leukocytes or inflammatory exudates.
Ischemia reperfusion injury.Micewere anesthetized by intraperitoneal injection of a
mixture of xylazine (80 mg/Kg) and ketamine (10 mg/Kg). Hind-limb ischemia was
initiated using tourniquets consisting of a rubber band placed on each hind limb as
in9. Ten min prior to the initiation of reperfusion n-3 DPA products (obtained as
described above) or Resolvin D1 (0.5 ng) were administered by intravenous injection
and compared to vehicle alone. At the end of this reperfusion period (2 h), mice were
euthanized and blood collected via cardiac puncture, lungs harvested, frozen in liquid
nitrogen and stored at280uC or stored in 10% (v/v) buffered formalin and processed
for histology by the Children’s Hospital Boston Core Histology Facility. The frozen
lungs were homogenized from individual mice, centrifuged and the tissue
myeloperoxidase (MPO) levels were determined using a mouse MPO ELISA (R&D
Systems.).
To investigate platelet leukocyte aggregates in murine whole blood after ischemia
reperfusion, blood was collected 2 h post reperfusion by cardiac puncture and
incubated with PE conjugated rat anti-mouse Ly6G and FITC conjugated rat anti-
mouse CD41 or relevant isotype controls for 30 min at 4uC. Red blood cells were lysed
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using ice-cold red-blood cell lysis buffer (BD Biosciences) and cells fixed with 1%
formalin prior to analysis by a BDCanto II. Data was analyzed using FlowJo (TreeStar
Inc.).
Sample extraction and lipidmediatormetabololipidomics.All samples for LC-MS-
MS analysis were extracted on SPE columns as in Ref. 41. Prior to extraction, 500 pg
of deuterium-labeled internal standards d8-5S-HETE, d4-LTB4, d5LXA4 and d4PGE2
were added to facilitate quantification of sample recovery.
The LC-MS-MS system, QTrap 5500 (ABSciex), was equipped with an Agilent
HP1100 binary pump and diode-array detector (DAD). An Agilent Eclipse Plus C18
column (100 mm3 4.6 mm3 1.8 mm) was used with a gradient of methanol/water/
acetic acid of 6054050.01 (v/v/v) to 1005050.01 at 0.4 ml/min flow rate. To monitor
and quantify the levels of the various LM, a multiple reaction monitoring (MRM)
method was developed with signature ion fragments for each molecule. Identification
was conducted using published criteria17 with at least six diagnostic ions. Calibration
curves were obtained using synthetic LM mixture (d8-5S-HETE, d4LTB4, d5LXA4,
d4PGE2, TXB2, PGD2, PGF2a, RvD1, RvD2, RvD5, Protectin (PD)1, Maresin 1
(MaR1), 17-hydroxydocosahexaenoic acid (17-HDHA), 14-hydroxydocosahexae-
noic acid (14-HDHA) and 7-hydroxydocosahexaenoic acid (7-HDHA) at 1, 10, 100,
275 pg. Linear calibration curves for each were obtained with r2 values in the range
0.98–0.99. Quantification was carried out based on peak area of theMultiple Reaction
Monitoring (MRM) transition and the linear calibration curve for each compound.
Where calibration curves for a structurally related DHA-derived product were not
available (14,21-diHDPA, 13,14-diHDPA and 16,17-diHDPA), levels were moni-
tored using a compound with similar physical properties.
For chiral lipidomic analysis, a Chiralpak AD-RH column (150 mm 3 2.1 mm 3
5 mm) was used with isocratic methanol/water/acetic acid 955550.01 (v/v/v) at
0.15 ml/min. To monitor isobaric monohydroxy docosapentaenoic acid levels, a
multiple reaction monitoring (MRM) method was developed using signature ion
fragments for each molecule.
Zymosan peritonitis. Zymosan (0.1 mg) was injected intraperitoneally (i.p.) in 1 ml
of sterile saline. Exudates were collected at 0, 4, 12 and 24 h post zymosan. Leukocyte
numbers and differential counts in the peritoneal exudates were determined as in16. In
designated experiments, mice were administered intravenously (i.v): Vehicle (saline
containing 0.1% EtOH), or the indicated mixture of n-3 DPA-derived products at
100 ng/mouse 5 min prior to i.p. zymosan administration (0.1 mg). After 4 h the
exudates were collected and the number of extravasated neutrophils determined
using Turks solution and flow cytometry as above.
Neutrophil isolation and chemotaxis. Peripheral blood neutrophils were obtained
from healthy volunteers as in Ref. 17. Briefly, neutrophils were prepared following
density separation by layering on Ficoll-Histopaque 1077-1. The cells were then
centrifuged at 300 g (30 min, 4uC), and contaminating red blood cells were lysed by
hypotonic lyses. These were then suspended at 1 3 106 cells/ml in DPBS containing
0.1% BSA and incubated with vehicle (0.1% EtOH in DPBS), RvD2 (1 nM) or the
indicated mixtures of n-3 DPA-derived products (1 nM) for 15 min at 37uC. 2.5 3
104 cells were then added to the upper chamber of the ChemoTx System (3 mm pore
size filter) and chemotaxis towards IL8 (100 ng/ml) was assessed (90 min, 37uC, 5%
CO2). The number of cells migrated into the bottom chamber was determined using
Alama Blue following manufacturer’s instructions on a Spectra Max M3 microplate
reader (Molecular Devices Inc., Sunnyvale, CA).
Human neutrophil-endothelial cell adhesion.HUVEC were purchased from Lonza
and cultured to passage 4. The cells were plated onto 96-well plates (Costar) coated
with 1% gelatin and incubated overnight. The HUVEC were then incubated with
TNF-a (10 ng/ml, 4 h, 37uC) in media containing 0.1% fetal bovine serum. Human
peripheral blood neutrophils were isolated as described above and labeled with CFDA
as in Ref. 17. These were then suspended in DPBS and incubated with vehicle (0.1%
EtOH) or the indicated mixture of n-3 DPA products (1 nM, 37uC, pH 7.45). After
15 min the PMN (1 3 105) were added to the HUVEC and incubated for 60 min
(37uC). The plates were thenwashedwithDPBS to remove non-adherent cells and the
number of adherent neutrophils assessed using a Spectra Max M3 microplate reader.
Endothelial cell adhesion molecule expression. HUVEC were plated onto 1%
gelatin coated 12-well plates and incubated overnight. Cells were then incubated with
vehicle (0.1% EtOH in DPBS) or the indicated mixture of n-3 DPA products for
15 min. The HUVEC were then incubated with TNF-a (10 ng/ml, 37uC) for 4 h. At
the end of these incubations, ICAM-1 levels were assessed by flow cytometry
following staining with fluorescently conjugated mouse anti-human ICAM-1
antibody (Clone HCD54; BioLegend) using the staining protocol17.
Macrophage preparation and phagocytosis. Macrophages were prepared and
phagocytosis was assessed as in Ref. 16. Briefly, cells were incubated with vehicle
(0.1% EtOH in DPBS), RvD2 (1 nM) or the indicated n-3 DPA products (1 nM) for
15 min at 37uC, then FITC-labeled zymosan was added and cells incubated 60 min at
37uC. Phagocytosis was assessed using an M3 SpectraMax plate reader.
Statistics. All results are expressed as means 6 SEM. Differences between groups
were compared using Student’s t test (2 groups) or 1-way ANOVA (multiple groups)
followed by post hoc Bonferroni test. The criterion for statistical significance was
P , 0.05.
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